Leukemia: Clinical Trials

Showing 49 trials
Title Investigatorsort icon
A Phase III Randomized Study of Expanded Umbilical Cord Blood Cells to Enhance Blood System Recovery in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 13-214]
Barker, Juliet, MBBS
Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
Relapsed/Refractory
[Protocol 12-153]
Barker, Juliet, MBBS
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087]
Barker, Juliet, MBBS
A Phase II Study of Treatment-Free Remission in Chronic-Phase Chronic Myelogenous Leukemia Patients Who Achieve and Sustain a Complete Molecular Response After Switching to Nilotinib
[Protocol 13-152]
Berman, Ellin, MD
A Phase III Study of Sapacitabine in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia
Newly Diagnosed
[Protocol 12-034]
Berman, Ellin, MD
A Phase II Study to Determine if Patients with Chronic Myelogenous Leukemia Who Respond Well to Nilotinib Can Stop Taking this Drug
[Protocol 13-111]
Berman, Ellin, MD
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
[Protocol 06-125]
Boulad, Farid, MD
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia
[Protocol 08-031]
Boulad, Farid, MD
A Phase I Study of Actinium-225-Labeled HuM195 Antibody in Patients with Advanced Myeloid Malignancies
[Protocol 02-017]
Douer, Dan, MD
A Phase I Study of BMS-906024 in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
Relapsed/Refractory
[Protocol 11-181]
Douer, Dan, MD
A Phase II Study of a Pediatric-Inspired Combination Chemotherapy Regimen in Adults with Acute Lymphoblastic Leukemia
[Protocol 12-266]
Douer, Dan, MD
A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-152]
Gerecitano, John, MD, PhD
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016]
Giralt, Sergio, MD
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077]
Goldberg, Jenna, MD
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251]
Horwitz, Steven, MD
A Phase I Study of Modified T Cells Targeted to CD19-Positive Acute Lymphoblastic Leukemia Relapsing After Allogeneic Stem Cell Transplantation
[Protocol 11-038]
Kernan, Nancy, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers
Relapsed/Refractory
[Protocol 12-142]
Lesokhin, Alexander, MD
A Phase II Trial of a WT-1 Vaccine in Patients with Acute Myeloid Leukemia
[Protocol 10-143]
Maslak, Peter, MD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024]
O'Reilly, Richard, MD
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053]
O'Reilly, Richard, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055]
O'Reilly, Richard, MD
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069]
Offit, Kenneth, MD
A Phase I/II Study of Oral Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Receiving a Stem Cell Transplant from a Donor
[Protocol 13-160]
Papadopoulos, Esperanza, MD
A Phase II Study of Midostaurin to Prevent Relapse After Allogeneic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
[Protocol 13-242]
Papadopoulos, Esperanza, MD
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038]
Papanicolaou, Genovefa, MD
A Phase II Study of Tretinoin plus Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Therapy
[Protocol 11-040]
Park, Jae, MD
A Phase I/II Study of Low-Dose Cytarabine and Lintuzumab-Ac-225 in Older Patients with Previously Untreated Acute Myeloid Leukemia
Newly Diagnosed
[Protocol 09-053]
Park, Jae, MD
A Phase II Study of Vemurafenib in Patients with Relapsed or Refractory Hairy Cell Leukemia
Relapsed/Refractory
[Protocol 12-200]
Park, Jae, MD
A Phase III Study of Inotuzumab Ozogamicin versus Standard Therapy in Patients with Persistent or Recurrent CD22-Positive Acute Lymphoblastic Leukemia
Relapsed/Refractory
[Protocol 12-262]
Park, Jae, MD
A Phase I/II Study Assessing BPX-501 T Cells Given After Partially Mismatched Related T Cell-Depleted Stem Cell Transplantation in Patients with Hematologic Cancers
[Protocol 13-181]
Perales, Miguel-Angel, MD
A Phase II Study of AUY922 in Patients with Myelofibrosis
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-076]
Rampal, Raajit, MD
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092]
Sauter, Craig, MD
Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia
[Protocol 11-002]
Shukla, Neerav, MD
A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib
[Protocol 11-030]
Shukla, Neerav, MD
A Phase I/II Study of PLX3397 to Treat Patients with Acute Myeloid Leukemia that Has Returned or Persisted Despite Therapy
Relapsed/Refractory
[Protocol 13-204]
Stein, Eytan, MD
A Phase I Study of Oral AG-120 to Treat Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH1 Mutation
[Protocol 14-052]
Stein, Eytan, MD
A Phase I Study of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia
[Protocol 13-137]
Stein, Eytan, MD
A Phase I Study of AG-221 in Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH2 Mutation
[Protocol 13-154]
Stein, Eytan, MD
A Phase IB/II Study of Vismodegib in Patients with Persistent or Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Relapsed/Refractory
[Protocol 13-183]
Tallman, Martin, MD
A Phase III Study of Clofarabine versus Standard Therapy for Newly Diagnosed Acute Myeloid Leukemia in Older Adults
Newly Diagnosed
[Protocol 12-059]
Tallman, Martin, MD
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181]
Tallman, Martin, MD
A Phase II Study of 5'-Azacitidine to Prevent Recurrence in Patients Who Had a Donated Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndromes
[Protocol 13-192]
Tamari, Roni, MD
A Phase I Study of Blinatumomab in Children and Adolescents with Relapsed/Refractory Acute Lymphoblastic Leukemia
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-044]
Trippett, Tanya, MD
A Phase I Study of SGN-CD19A in Children and Adults with Persistent B-Cell Acute Lymphoblastic Leukemia or Aggressive Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 13-106]
Trippett, Tanya, MD
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224]
Zelenetz, Andrew, MD, PhD
A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Relapsed/Refractory
[Protocol 13-252]
Zelenetz, Andrew, MD, PhD
A Phase III Study of Bendamustine and Rituximab plus GS-1101 (CAL-101) or Placebo for Previously Treated Chronic Lymphocytic Leukemia
[Protocol 12-189]
Zelenetz, Andrew, MD, PhD